Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes

Christopher R. Cogle(University of Florida), Fatih M. Uckun(University of Southern California), Leslie Pettiford(University of Florida), Elizabeth Wise(University of Florida), Zackary Beachamp(University of Florida), Bradley R. Collins(University of Florida), Raphael C. Bosse(University of Florida), Randall W. Brown, Kimberly E. Hawkins(University of Florida), Jan S. Moreb(University of Florida), Daniel Turner(University of Florida), John Hiemenz(Moffitt Cancer Center), Christina Cline(University of Florida), W. Stratford May(City of Cape Town), John R. Wingard(University of Florida Health), Jack W. Hsu(University of Florida Health), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
British Journal of Haematology
April 1, 2020
Cited by 15


Related Papers